31 – 40 of 98
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Why do ‘OFF’ periods still occur during continuous drug delivery in Parkinson’s disease?
(
- Contribution to journal › Scientific review
-
Mark
High risk of developing dementia in Parkinson’s disease : a Swedish registry-based study
(
- Contribution to journal › Article
-
Mark
Objective Observer vs. Patient Motor State Assessments Using the PD Home Diary in Advanced Parkinson's Disease
(
- Contribution to journal › Article
-
Mark
Safinamide in the treatment pathway of Parkinson’s Disease : a European Delphi Consensus
(
- Contribution to journal › Article
- 2021
-
Mark
Validation and clinical value of the MANAGE-PD tool : A clinician-reported tool to identify Parkinson's disease patients inadequately controlled on oral medications
(
- Contribution to journal › Article
-
Mark
Parkinson's Disease and Post–COVID-19 Syndrome : The Parkinson's Long-COVID Spectrum
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on ‘Off’-time in Patients with Advanced Parkinson’s Disease : A Systematic Review
(
- Contribution to journal › Scientific review
-
Mark
Parkinson’s disease in Sweden—resource use and costs by severity
(
- Contribution to journal › Article
-
Mark
Effects of safinamide on pain in patients with fluctuating Parkinson's disease
(
- Contribution to journal › Article
-
Mark
Clinical Usefulness of Retropulsion Tests in Persons with Mild to Moderate Parkinson’s Disease
(
- Contribution to journal › Article